Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

NCT02203825 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Multiple Myeloma

Interventions

BIOLOGICAL: CM-CS1 T-cell infusion

Sponsor

Celyad Oncology SA

Collaborators

[object Object]
[object Object]